Informations:
Erreur:
ID
33350
Description
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00796107
Lien
https://clinicaltrials.gov/show/NCT00796107
Mots-clés
Versions (1)
- 06/12/2018 06/12/2018 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
6 décembre 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Breast Cancer NCT00796107
Eligibility Breast Cancer NCT00796107
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00796107
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Postmenopausal state
Item
postmenopausal female patients;
boolean
C0232970 (UMLS CUI [1])
Secondary malignant neoplasm of female breast | Locally advanced breast cancer
Item
stage iv or locally advanced breast cancer;
boolean
C0346993 (UMLS CUI [1])
C3495949 (UMLS CUI [2])
C3495949 (UMLS CUI [2])
Measurable Disease
Item
measurable disease;
boolean
C1513041 (UMLS CUI [1])
Letrozole failed
Item
letrozole failure (part 2);
boolean
C0246421 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,2])
ECOG performance status
Item
ecog performance status <=2.
boolean
C1520224 (UMLS CUI [1])
Prior Chemotherapy Secondary malignant neoplasm of female breast
Item
previous chemotherapy for metastatic breast cancer;
boolean
C1514457 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,2])
Antibody therapy Advanced disease | Immunotherapy Advanced disease
Item
concurrent antibody or immunotherapy for advanced disease, within 4 weeks prior to receipt of study drug;
boolean
C0281176 (UMLS CUI [1,1])
C0679246 (UMLS CUI [1,2])
C0021083 (UMLS CUI [2,1])
C0679246 (UMLS CUI [2,2])
C0679246 (UMLS CUI [1,2])
C0021083 (UMLS CUI [2,1])
C0679246 (UMLS CUI [2,2])
Primary tumor | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in situ of uterine cervix
Item
history of primary malignancy in 5 years prior to study, excluding adequately treated basal or squamous cell cancer of skin, or cancer in situ of cervix;
boolean
C0677930 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0851140 (UMLS CUI [4,2])
Therapeutic radiology procedure
Item
concurrent radiotherapy, or radiotherapy within 28 days prior to receipt of study drug.
boolean
C1522449 (UMLS CUI [1])